+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05773274

Comparing Retreatment with 177Lu-DOTATATE PRRT Versus Everolimus, Sunitinib, or Cabozantinib for Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors

Led by National Cancer Institute (NCI) · Updated on 2026-11-03

100

Participants Needed

43

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy PRRT compared to usual treatments such as everolimus, sunitinib, or cabozantinib in patients with metastatic, unresectable gastroenteropancreatic neuroendocrine tumors GEPNET who have previously received 177Lu-DOTATATE. This phase II trial aims to assess which treatment better delays tumor progression and improves survival and quality of life in this patient group. PRRT uses a targeted radioactive peptide to kill tumor cells while limiting damage to normal cells. Participants are randomly assigned to one of two study groups. One group receives 177Lu-DOTATATE intravenously every 8 weeks for two cycles if their disease does not worsen or they do not experience severe side effects. The other group takes oral medicationseverolimus daily, or sunitinib for pancreatic NET patients, or cabozantinib for U.S. patientsuntil disease progression or unacceptable toxicity. Imaging scans and blood samples are collected during the study to monitor disease status and treatment effects. Patients whose cancer worsens while on oral medications may cross over to receive 177Lu-DOTATATE. Throughout the trial, participants attend regular visits for CT or MRI scans and blood sample collections. After completing study treatment, they are followed every 12 weeks until the disease progresses and every 6 months thereafter until death. Researchers measure progression-free survival as the main outcome, along with overall survival, response rate, safety, patient quality of life, and other disease progression markers. These assessments will provide comprehensive data on the effects and safety of retreating with 177Lu-DOTATATE compared to other treatments.

CONDITIONS

Brief Title

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here